Navigation Links
Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today the Company will relocate its corporate headquarters to Cambridge, MA from Laguna Niguel, CA.  The move is integral to Inspiration's plan to accommodate its anticipated future staffing and facility needs as the Company transitions to product commercialization.

Inspiration's new location at One Kendall Square is ideally located within the greater Boston area's technology and life sciences cluster.  The new address is:

Inspiration Biopharmaceuticals
One Kendall Square
Cambridge, MA 02139

John P. Butler, Chief Executive Officer of Inspiration, commented, "The Boston metro area has always been a center for growth and innovation in the biopharmaceutical industry.  As we move toward the launch of Inspiration's first products, including IB1001, our recombinant factor IX product for hemophilia B, it is the perfect location to establish our corporate office.  We expect the close proximity to some of the leading academic and research institutions will help attract top talent as we continue to build a world-class company focused on improving the life of individuals with hemophilia."

In October 2011, Inspiration named John P. Butler Chief Executive Officer.  Mr. Butler joined Inspiration from Cambridge-based Genzyme Corporation, where he most recently served as President of the company's rare genetic diseases business.

One Kendall Square is in the heart of Cambridge's life-sciences community.  Since its inception, this address has served as headquarters for many early-stage to mid-tier companies, including a number that have gone on to develop blockbuster drugs and employ thousands of workers in Greater Boston.  The office and research park is situated on nine acres.

About Inspiration Biopharmaceuticals
Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care to safe and effective recombinant therapies and advance innovation for people living with these conditions.  Inspiration has a broad portfolio of recombinant hemophilia products, which includes two products in late-stage clinical development and two preclinical programs.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B, and OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product for the treatment of individuals with congenital hemophilia A who have developed inhibitors against human FVIII and for individuals with acquired hemophilia.  Inspiration recently submitted its first marketing application for IB1001 in Europe, with a subsequent regulatory filing planned in the U.S.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa), for individuals with either hemophilia A or hemophilia B who have developed inhibitors, and for individuals with factor VII deficiency; and human recombinant FVIII, to treat individuals with hemophilia A.

Inspiration's senior management team has broad experience and expertise in hemophilia product development, biologics manufacturing and the successful commercialization of products to treat both hemophilia as well as chronic orphan diseases.

In addition, in January 2010, Inspiration entered into a strategic partnership with the Ipsen Group (EURONEXT: IPN; ADR: IPSEY), leveraging the combined expertise and resources of the two companies, to develop a broad portfolio of hemophilia products.  As announced in late August 2011, Ipsen and Inspiration extended their partnership to create a hemophilia business unit structure that will act as the exclusive sales organization for all hemophilia products commercialized under the Inspiration brand in Europe.  For further information on Inspiration, please visit

 Contacts: MediaCompanyJustin JacksonGordon H. BusenbarkMichelle SzwarcbergSenior Vice President, Chief Financial OfficerBurns McClellanEmail: Tel: +1-212-213-0006




SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
6. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
7. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
8. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
11. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
Post Your Comments:
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:10/27/2015)... 27, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... Google has adopted the Synaptics ® ClearPad ® ... power its newest flagship smartphones, the Nexus 5X by ... --> --> Synaptics works ... strategic collaboration in the joint development of next generation ...
(Date:10/26/2015)... ALTO, Calif. and LAS VEGAS ... Nok Nok Labs , an innovator in modern ... Alliance , today announced the launch of its latest ... first unified platform enabling organizations to use standards-based authentication ... The Nok Nok S3 Authentication Suite is ideal for ...
(Date:10/23/2015)... Research and Markets ( ) has announced the ... 2015-2019" report to their offering. ... recognition biometrics market to grow at a CAGR of ... --> The report, Global Voice Recognition Biometrics ... market analysis with inputs from industry experts. The report ...
Breaking Biology News(10 mins):